08329.HK
Shenzhen Neptunus Interlong Bio-technique Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 0.10
−6.67%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1B | 972.0M | 1.0B | 1.1B | 986.7M |
| Cost of Revenue | 797.4M | 684.8M | 713.7M | 625.6M | 542.5M |
| Gross Profit | 326.9M | 287.2M | 328.0M | 439.2M | 444.1M |
| Operating Expenses | |||||
| R&D Expense | 36.9M | 32.7M | 33.1M | 46.2M | 28.7M |
| SG&A Expense | 272.0M | 231.3M | 256.3M | 343.3M | 338.0M |
| General & Admin Expense | 72.6M | 94.9M | 93.9M | 90.4M | 93.7M |
| Selling & Marketing Expense | 91.6M | 136.4M | 162.4M | 252.8M | 244.2M |
| Other Expenses | 71.7M | 67.6M | 3.9M | 13.5M | (11.8M) |
| Total Operating Expenses | 380.5M | 331.6M | 293.3M | 403.0M | 354.8M |
| Cost and Expenses | 1.2B | 1.0B | 1.0B | 1.0B | 897.4M |
| Operating Income (EBIT) | (53.5M) | (44.4M) | 34.7M | 36.2M | 89.3M |
| Non-Operating | |||||
| Interest Income | 841.9K | 2.0M | 3.7M | 6.3M | 6.5M |
| Interest Expense | 5.2M | 4.1M | 5.1M | 5.6M | 7.0M |
| Net Interest Income | (4.1M) | (2.1M) | (1.4M) | 688.0K | (561.0K) |
| Other Non-Op Income/Expense | (3.1M) | (4.1M) | (5.1M) | (5.6M) | (7.0M) |
| Non-Operating Income (excl Interest) | (65.3M) | (65.0M) | — | — | — |
| EBT (Pre-Tax Income) | (56.6M) | (48.6M) | 29.6M | 30.7M | 82.3M |
| Income Tax Expense | 5.3M | 4.5M | 15.9M | 16.1M | 18.4M |
| Bottom Line | |||||
| Net Income | (49.3M) | (40.7M) | 25.0M | 24.1M | 54.3M |
| Earnings from Cont. Ops | (61.9M) | (53.1M) | 13.8M | 14.5M | 63.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (49.3M) | (40.7M) | 25.0M | 24.1M | 54.3M |
| Per Share | |||||
| Basic EPS | (HK$0.03) | (HK$0.02) | HK$0.01 | HK$0.01 | HK$0.03 |
| Diluted EPS | (HK$0.03) | (HK$0.02) | HK$0.01 | HK$0.01 | HK$0.03 |
| Revenue Per Share | HK$0.67 | HK$0.58 | HK$0.62 | HK$0.63 | HK$0.59 |
| Shares | |||||
| Basic Shares Outstanding | 1.7B | 1.7B | 1.7B | 1.7B | 1.7B |
| Diluted Shares Outstanding | 1.7B | 1.7B | 1.7B | 1.7B | 1.7B |
| Profitability Metrics | |||||
| EBITDA | 48.4M | 48.1M | 62.9M | 69.9M | 125.2M |
| D&A | 36.7M | 27.5M | 28.1M | 33.6M | 35.9M |
| EBIT | 11.8M | 20.6M | 34.7M | 36.2M | 89.3M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026